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ABSTRACT

In nuclear pre-mRNA splicing, introns are removed through cooperative interactions of
small nuclear RNAs (snRNAs). Many human genes are interrupted by two types of
nuclear pre-mRNA introns. Major class or the U2-dependent type introns are spliced by
U1, U2, U4, U5 and U6 snRNAs. The minor class or U12-dependent type introns are
spliced by U11, U12, U4atac, U5, and U6atac snRNAs. It has been shown that over
expression of minor class spliceosomal snRNAs can have an inhibitory effect on the
splicing of major class introns. To further test the concept, we targeted HER-2/Neu protooncogene, which is over-expressed in 20-30% of human mammary tumors. We
constructed a series of mutant human U6atac and U11 snRNAs to target 5’ splice site of
introns 1, 2, 6, 8, 12 and 13 of HER-2/Neu in order to prevent nuclear pre-mRNA
splicing and to down regulate protein synthesis. To determine the efficacy of our
approach, we transiently expressed mutant snRNAs in mammary carcinoma cells to
activate splicing interference (SPLICEi) of HER-2/Neu pre-mRNA. Our data indicates
that the modulation of HER-2/Neu pre-mRNA by mutant snRNAs mediated SPLICEi
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affect the protein expression in cultured cells. Furthermore, albeit modest, we observed
inhibition of cancer cell proliferation and activation of apoptosis. Although, our approach
is still at experimental stages, it presents another opportunity for targeting of oncogenes
at RNA level.
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CHAPTER I
INTRODUCTION

1.1 Gene Expression
Currently, the most abundant mode of treatment for cancer is chemotherapy,
which chemically poison the body tissues in an attempt to destroy the cancerous cells.
Chemotherapy is highly toxic yet not specific. Along the same approach is an attempt
to treat cancer by a very broad scope is radiation therapy. Radiation therapy uses
harmful radiation in the same manner as chemotherapy to treat cancer. The outcome
is just as grim with the side effects being very just as catastrophic ranging from
nausea and hair loss to mouth sores.
Recent advancement in research has made the possibility of more specific
types of cancer therapy using genetic approaches. Now that specific human genome
sequence is known, researchers are taking advantage of bioinformatics in attempts to

1

develop more specific gene targeted therapies. Many studies have been done to
understand the molecular and cellular pathways involved in gene expression.
The “central dogma” of molecular biology states that development of a cell is
governed by a series of intrinsically orchestrated cellular events in gene expression.
Gene expression begins with DNA coded information being transcribed to RNA and
RNA in turn is translated to proteins, which affects cellular functions (Zhou, 2010).
Genetic transcriptional and translational events are the building blocks of molecular
biology and are stringently regulated at several steps (Hartwell et al, 2004). It because
of new insight into these steps that enable researcher to develop more direct
approaches to treatment of various diseases, including cancer.
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During the transcriptional processes from DNA to RNA there are molecules
involved to ensure the accurate synthesis of functional RNA. In disease cells the
intrinsic machinery to ensure protein synthesis from DNA is perturbed and needs to
be targeted to resume proper function. Nucleic acid therapy targets the transcriptional
aspect of this machinery in attempts to specifically target the perturbation.

1.2 Strategies For Gene Targeting
Currently there are some therapies for different types of cancer as well as
other diseases that are nucleic acid based. These therapies include targeting diseases
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using antisense olidonucleotides, small interfering RNA (siRNA), and micro RNA
(miRNA).

1.2.1 Antisense oligonucleotides
Antisense oligonucleotides (AO) are short nucleic acids designed to bind to
specific sequences of pre-mRNAs in an attempt to manipulate mRNA splicing that
can eventually affect protein synthesis. The goal of this type of genetic therapy is to
modulate the expression of the specific gene through alternative splicing (Goyenvalle
et al. 2011).
Gene therapy can have either translational suppressive capability (anti-sense
oligonucleotides [oligos]) or replacement (of inactivated, mutated or deleted
suppressor genes such as PTEN) techniques (Huang et al. 2001). Both tumor and
normal cells express the same genes that differ in expression levels. Gene
therapeutics can be incorporated in the cell proliferation and growth of tumors, but
resistance eventually develop because the endogenous biochemical pathways of the
cell are complex and highly regulated by many factors that are easily altered. It has
been suggested that tumors can change their dependence upon one factor by relying
upon others through compensation (Rubenstein et al. 2011).
Progress has been made in the development of drug therapy using antisense
oligonucleotides but it still face obstacles including, but not limited to, effectively
delivering drugs containing AO, and properly regulating the outcome of this therapy.
Splicing is a nuclear event and AO has to be delivered to specific cell types without
the pre-mRNA degradation before splicing. The delivery mechanism currently
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available is slow and relatively ineffective. Another very substantial problem is the
toxicity experienced but the non-targeted cells.

1.2.2 Small Interfering RNA (siRNA)
Small interfering RNA (siRNA) is a double stranded RNA molecule that is
involved in mRNA cleavage at specific sequences. Because of this specificity, siRNA
is frequently used effectively in RNA interference methods in the down regulation of
genes involved in diseases (Gao et al, 2011).
RNA interference was discovered in Caenorhabditis elegans (C. elegans) in 1985.
RNA interference, a process that requires sequence-specificity, it is posttranscriptional gene silencing directed by short interfering 21–23 nucleotide doublestranded RNA (siRNA) while specifically and dramatically reducing the expression
of its targeted mRNA. In siRNA therapeutics, a lot of vectors for siRNA delivery
have been reported to achieve perfect results with in vitro applications, but these
vectors were mostly inappropriate for use in vivo or are only administered locally. To
be administered systemically, targeted siRNA delivery should be designed to improve
accumulation of siRNA at three levels; the target tissue, target cell, and intracellular
target site of action (Lu et al. 2011)
However, siRNA are highly unstable molecules. Problems hindering effective
therapeutic application lie predominantly in their delivery, stability, and off-target
effects. Reliable effective delivery systems can provide solutions to many of the
challenges facing siRNA therapeutics. Due to some fatal disadvantages of using viral
vectors, nonviral carriers are being studied extensively. Aside from liposomes,
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nanoparticles and cationic polymer, carriers have exhibited improved in vivo stability,
better biocompatibility, and efficiency for gene silencing, but cellular toxicity still
remain problematic (Allain et al, 2011).

1.2.3 MicroRNA (miRNA)
MicroRNAs (miRNAs) are small stretches of non-coding sequences that are
(does not transcribe for a protein) RNA molecule which are involved in regulating
gene expression. Their presence has been shown to have implications to be in
numerous cellular processes such as cell proliferation and differentiation. Hundreds of
miRNAs have been shown to play a role in diseases including cancer. miRNAs are
important regulators of genes, and when their expression levels are abnormal it can
lead to disease. Deregulation of key components of the miRNA machinery have been
shown in cancer to alter expression of miRNAs and shown to play a major role in
pathogenesis (Rupaimoole et al, 2011).
Inhibiting mRNA translation using miRNAs could soon represent a valid option
for the treatment of specific patients. A specific case described in detail by Hui Ling
et al. (2011) shows the use of miRNAs inhibited translation as a way to treat chronic
lymphocytic leukemia (CLL). According to Ling, there would be two advantages to
using miRNAs: 1) miRNAs are a natural product produced in human cells (unlike
chemotherapeutic agents or antisense oligonucleotides), and 2) miRNAs target
multiple genes from the same pathway and therefore the action occurs at multiple
levels in the same pathway (for example, miR-16 targets both antiapoptotic genes
Bcl-2 and Mcl-1) (Ling et al, 2011).
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MicroRNA therapy is an emerging field but there is still much to be established
about these non-coding RNAs. Since, microRNAs do not need perfect complimentary
to have an effect, off target effects still pose a major problem. A more general
problem with microRNA therapeutics is the inadequate delivery system in place to
have the desired effect.

1.3 Small Nuclear RNA (snRNA)
The foundation for our study is the targeting the RNA:RNA interactions that
take place between pre-mRNA and small nuclear RNAs (snRNA). snRNA is a group
of RNA molecules that is crucial to pre-mRNA splicing process (Fischer et al, 2011).
Splicing is the removal for introns and the ligation of the exons. Introns are the
untranslated noncoding region of DNA, whereas the exon is the translated coded
region of RNA. After splicing occurs a mature mRNA transcript is ready to be
translated into the corresponding protein.
Small Nuclear Ribonucleoprotein (snRNP) - are complexes formed with small
nuclear RNAs and their respective proteins to facilitate splicing. The major class of
spliceosome includes U1, U2, U4, U5, and U6 snRNAs. The minor class of
spliceosome includes, U11, U12, U4ATAC, U5 (same as in major class), and
U6ATAC snRNAs (Shukla et al, 2004).
The four snRNAs that are unique to each of the spliceosomal machineries
have been shown to have analogous functions. Therefore, U11 snRNA is the
functional analog of U1 snRNA, U12 snRNA is the analog of U2 snRNA, U4atac
snRNA is the analog of U4 snRNA, and U6atac snRNA is the analog of U6 snRNA.
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U5 snRNA appears to function in both spliceosomes. These analogies are based, in
large part, on the similarities in RNA:RNA interactions displayed by the respective
snRNAs. (Shukla et al, 2004).

snRNAs DEPICTING THEIR CORRESPONDING FUNCTIONAL ANALOGS

MAJOR CLASS (U2-dependent)

MINOR CLASS (U12-dependent)

U1

U11

U2

U12

U4

U4ATAC

U5

U5

U6

U6ATAC

1.4 Nuclear Precursor mRNA (pre-mRNA) Splicing
Splicing is a dynamic chemical process that occurs through the formation of
spliceosomal complex. The spliceosomal complex is a ribonucleoprotein complex
consisting of the 5 snRNAs and more than 300 auxillary proteins which aids in
splicing effiency. Splicing convert the pre-mRNA to the mRNA through two
transesterification reactions that is presumably catalyzes by an RNA (Newman et al,
1995).
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The pre-mRNA is made up a 5’ exon followed by an intron which contains;
splice site consensus sequence (differs in major and minor class introns) at the
exon/intron boundary, a branch site sequence containing a conserved adenine, a
polypyrimidine tract (only in major class introns), a 3’ splice site consensus sequence
(differs between major and minor class) at the intron/exon boundary, and a 3’ exon
(Will et al, 2005).
The first transesterification reaction occurs when the 2’OH from the adenine
attacks the phosphodiester bond at the 5’splice site, freeing the exon 1, leaving a lariat
shaped intron and the following exon. The second transesterification reaction occurs
when the 3’OH from the 5’ exon attacks the phosphodiester bond between the intron
and the 3’ exon. The products are the exons spliced together and the intron lariat was
removed. Figure 2.
U2 and U12 dependent introns are depicted by short conserved sequences ate
the 5’ splice site, 3’ splice and branch site. U12 dependent introns was first
recognized by Jackson (1991) and Hall and Padgett (1994) because of the terminal
dinucleotides of the U12 dependent contained AT at the 5’ splice site and AC at the
3’ splice site (Burge et al. 1998). This observation in intronic sequence broke the
previously observed GT at the 5�splice site and AG at the 3’ splice site of U2
dependent introns.
U2 dependent class of spliceosomes is responsible for over 99% of all the
splicing of pre-mRNA that occurs in eukaryotic cells and is subsequently referred to
as major class splieosomes. Consequently, less than 1% of splicing of eukaryotic premRNA is done by minor class spliceosomes (Burge et al. 1998)
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Figure 2
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As reported by Shukla et al, (2004), U12 dependent snRNAs are capable of
binding to U2 dependent introns, we proposed that mutants of U12-dependent
snRNAs, U11 and U6atac, to bind complementarily the 5’ splice site of the major
class intron, should cause splicing interference (SPLICEi) in the gene. To test this
model we chose the HER-2/Neu gene, a gene spliced through the U2 dependent
pathway, and is over-expressed in specific type of aggressive mammary carcinoma.

Currently, nucleic acid therapeutics mainly target genes post-transcriptionally.
Targeting the snRNAs and pre-mRNA binding, is a novel approach in targeting
diseases in the pre-mRNA stage. Understanding the RNA:RNA base-pairing that
occurs between the pre-mRNA and the snRNAs, as well as the HER-2 gene sequence,
we mutated specific nucleotides of the snRNAs (U6ATATC and U11) to forcibly
cause the HER-2 gene to bind with the U12-dependent snRNAs in attempts to downregulate the gene expression, activating SPLICEi.
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1.5 HER-2/Neu Gene and Mammary Carcinoma
Human epidermal growth receptor- 2 (HER-2/Neu), is a transmembrane
receptor tyrosine kinase (Shigematsu et al, 2011). HER-2/Neu protooncogene is overexpressed in nearly 20%–40% of breast carcinomas, and its expression levels has
been used an indicator of tumor aggressiveness and poor prognosis (Skalova et al,
2011). HER-2/neu has become an essential part of the clinical evaluation of breast
cancer patients. Currently HER-2+ patients are treated with a humanized monoclonal
antibody trastuzumab (Herceptin; Genentech, San Francisco, CA, USA). (Kapila et
al, 2011)
Trastuzumab shows clinical activity in women with HER2/neuoverexpressing metastatic breast cancer antitumor effects when combined with
paclitaxel or anthracyclines, other available cancer treatment drugs, achieving an
overall response of 40%–60% of the patients observed (Kapila et al, 2011). In spite of
its efficacy of drug cocktail, the response to trastuzumab only is 7%–35%, depending
on the level of HER2/neu expression, and the median duration of response is less than
9 months (Costantini et al).
HER-2 gene contains 26 exons and 25 introns and to test our hypothesis we
generated U6ATAC and U11 snRNAs containing complementary nucleotides to
base-pair with the 5’ splice sites of HER-2/Neu pre-mRNA. The targeted introns are
shown in figure 3 (Introns: 1, 2, 6, 8, 12,and 13). Splicing interference or SPLICEi
was be introduced by liposome based transient transfections of the modified snRNAs
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and the consequence of HER-2/Neu SPLICEi mediated repression was studied using
various cell and molecular techniques.

Figure 3: Schematic diagram of the HER-2/Neu gene structure: Orange bars
correspond to the exons and blue line, the introns. The red color stem-loop signifies
the targeted binding of U6ATAC and U11 to the 5’ splice-site of multiple introns.
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CHAPTER II
MATERIALS AND METHODS

2.1 Cell lines
MDA-MB-453

Adherent epithelial cells derived from human female mammary gland (breast) with
metastatic carcinoma. MDA-MB-453 over-express HER-2 gene which is a marker for
breast cancer. Chan et al. (1995), was able to shown the overexpression of HER2/Neu in the MDA-MB-453 cell line.
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T-47D

Adherent epithelial cells derived from h uman female mammary (breast) duct with
ductal carcinoma. The HER-2 gene is used as a marker in breast cancer, and is
overexpressed in T-47D cells. Based on research done by Lyons et al. (2001), T-47D
has a threefold increase of the copy of HER-2/Neu gene.

2.2 Mammary Carcinoma Cell Culture
MDA-MB-453 and T-47D cells were obtained from the ATCC to be used . Cells
were cultured in Dulbecco Modified Eagle Medium (DMEM), 10% Fetal Bovine
Serum (FBS), 1% Penicillin:Streptomycin (Pen-strep). Both cell-lines were incubated
in 5% Carbon dioxide (CO2) in 37C, on 100 mm culture plates. MDA-MB-453 cells
were split maximum 1:4 ratio, and T-47D were split maximum 1:6 ratio.

2.3 Mutagenesis
In order to introduce the sequence mutations desired we did mutagenesis
reactions. The mutagenesis reactions were done using Change-IT Multiple Mutation
Site Directed Mutagenesis Kit. A 20l reaction was done using 5ng of DNA template.
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Each reaction mixture included 10X buffer, 5M amp forward, 5M of mutant
primer, and 0.8l Change-it enzyme. The PCR conditions consisted of a denaturing
step (95C, 2 min) followed by 37 cycles (95C, 30 sec; 53C, 30 sec; 68C, 35 min)
and a final extension step (68C, 20min). The 10l of reaction was then DPN-1
treated using 1l of DPN-1 enzyme and incubated at 37C for 2hrs. After, additional
0.5l DPN-1 was added and incubated at 37C for 1hr.

2.4 Transformation
To introduce the mutated DNA into the MDA-MB-453 and T-47D cells, E.
coli cells were first transformed with the matant DNA sequence using the following
procedure. 4l of the DPN-1 treated reaction from mutagenesis was added to 100l of
DH5 E.coli competent cells kept on ice for 30 min then given a 42C heat shock for
50 sec and placed back on ice for 2 min. 900l of Luria Bertani (LB) Broth was
added to the DH5 cells and spin for 7 min discarding the supernatant. Add 100l of
LB and plate cells on LB/Ampicillin plate and incubate at 37C for 12-16hrs.
Colonies were picked and placed in 4ml of LB containing ampicillin overnight in
shaker at 250 rpm at 37C, after stored 4C to be used for mini-prep. All the steps
were done aseptically.

2.5 Miniprep
To extract the plasmid DNA from the competent cells miniprep was done
using the following procedure. Miniprep was done using Zyppy Plasmid Miniprep
Kit. In brief, using 600l of bacterial culture grown in LB medium add 100l of 7X
16

lysis buffer, neutralizing with 350l Neutralization buffer and centrifuged. The
supernatant was transferred to the zymo-spin IIN column and centrifuged. Discarding
the follow through, the column was washed 2x with zippy wash buffer and
centrifuged. The column was placed in clean microcentrifuge tube 30l of elution
buffer was added directly to the column and centrifuged after 1min of standing at
room temperature. The plasmid DNA was collected in the clean microcentrifuge tube
after centrifugation.

2.6 Maxiprep
To obtain a high yield of the desired plasmid DNA maxiprep was done with
the following procedure. Maxi-prep was done using Qiagen Maxi Kit. RNase A
solution was added to buffer P1, buffer P3 was pre-chilled to 4C. In brief, 500l of
overnight LB culture was centriguged at 4C for 15 min. Pellet was resuspended in
buffer P1, buffer P2 was then added and sample was mixed thoroughly and incubated
at room temperature for 5 min. Buffer P3 was added and sample was centrifuged at
4C for 30 min. The supernantant was re-centrifuged at 4C for 15 min. Qiagen-tip
was equilibriated with 10ml of buffer QBT and column was allowed to empty by
gravity flow. DNA was eluted with buffer QF in a clean vessel. Isopropanol was
added to precipitate DNA and kept overnight at -20C. After centrifugation the DNA
pellet was washed with 70% ethanol. Pellet was allowed to air-dry and re-dissolved in
100l of TE buffer.
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2.7 Transfection
To introduce the mutations into the mammary carcinoma cell lines they
needed to be transfected. Transfection was done using Roche Fugene 6 tranfection
reagent. Transfection was done in 3:2 ratio (3l of Fugene 6 with 2g of mutant DNA
constructs). Transfections were done in 6-well plates. In brief, cells were plated in 6well plates in antibiotic-free media overnight. 24hrs after, 3l fugene-6 reagent and
2g DNA were added to 100l of antibiotic-free serum-free media per well. The
media containing fugene-6 and DNA was added directly to plated cells and incubated
for 48hrs at 37C 5% CO2.

2.8 RNA Extraction Using TRIzol Reagent
In order to extract RNA from the transfected cells TRIzol reagent was used
according to the following procedure. In brief, media was aspirated and 1ml TRIzol
was added directly to cells. The lysate was passed through the pipette several times
and collected in microcentrifuge tubes. 200l of chloroform was added to each tube
shaking vigorously. Samples were centrifuged and the aqueous phase was collected in
fresh microcentrifuge tube. 500l of isopropanol and centrifuged at 4C for 10 min.
Pellet was wash with 75% ethanol vortexed and centrifuged at 4C for 10 min. RNA
pellet was air-dried then dissolved in 30l RNase-free water. Sample was incubated
at 55C for 10 min to resolubilize the RNA and stored at -80C for future use.
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2.9 Removal of Nuclear DNA Contamination from Total RNA
The total RNA was purified of nuclear DNA contamination using Promega
Kit. In brief, to each sample 10l RQ1 10X buffer + 10l RQ1 Dnase enzyme was
added and incubated at 37C for 20 min. Additional 5l of DNase enzyme was added
to each sample and incubated for at 37C for 20 min then centrifuged. 100l phenol
chloroform was added vortexed then centrifuges for 5 min. Upper phase was
collected in fresh microcentrifuge tube. 35l chloroform was added, sample was
vortexed, and centrifuged. The upper aqueous phase was collected in fresh
microcentrifuge tube, sodium acetate 1/10th the collected volume was added + 1l
glycogen and vortexed. 2 ½ total volume 100% ethanol was added, mixed, and stored
at -80C overnight. Samples were centrifuged at 4C for 30 min, the RNA pellet
washed with 250l 75% ethanol/DEPC treated water and re-centrifuged. RNA Pellet
was air-dried and re-suspended in 20l DEPC treated water. Samples were heated at
50C for 15 min to resolubilzes RNA and placed at -80C for future use.

2.10 cDNA Synthesis
In brief, using Promega- Improm-II Reverse Transcription System 0.5g RNA
was incubated with 10M reverse transcription primer at 70C for 5 min. Using
25mM magnesium chloride and 0.5mM, 0.5l recombinant RNasin ribonuclease
inhibitor, and 1l Improm-II reverse transcriptase. The reaction mixture was placed in
thermal cycler at 25C, 5 min; 42C, 60 min; 70C, 15min.
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2.11 Polymerase Chain Reaction
DNA synthesized was amplified using Promega - GoTaq PCR core systems a
reaction containing 2mM magnesium chloride, 5nM gene specific forward primer,
5nM gene specific reverse primer, 0.125l Go Taq DNA polymerase, and 1l cDNA
template. The PCR conditions consisted of a denaturing step (94C, 3 min) followed
by 24 cycles (94C, 1 min; 55C, 1.05 min), and extension step (70C, 1 min).

2.12 Quantitative Real Time – Polymerase Chain Reaction (qRT-PCR)
Using SYBR GreenER qPCR super mix 20l reactions were done with 0.1nM
forward and reverse primers, and 1l cDNA template. The PCR conditions consisted
of pre-cycling stage (50C, 2 min), followed by denaturation step (95C, 10 min),
then 40 cycles (95C, 15 sec; 60C, 1 min). Melt curve was obtained with 100% ramp
(95C, 15 sec; 60C, 1 min), +0.3 (60C, 1 min; 95C, 15 sec). In these experiments
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal
control to compare gene expression from the HER-2/Neu data obtained.

2.13 Total Cell Lysate
To obtain total cell lysate from transfected cells, they were lysed using lysis
buffer containing 98% M-PER reagent, 1% phosphatase inhibitor cocktail 2 (Sigma),
and 1% protease inhibitor cocktail. 70l of lysis buffer was added to each sample and
placed in shaker at 900 rpm, 4C, for 40 min. The supernatant was collected for future
experiments. Bradford assay was done to determine the protein concentration.

20

2.14 Western Blot Analysis
To observe the protein product of the HER-2/Neu gene total cell lysate was
analyzed by electrophoresis. Using NuPAGE 4-12% Bis-Tris Gel 1.5mm x 15well
precast gel (Invitrogen) electrphoresis was done using 1X NuPAGE MOPS SDS
running buffer. 5g of proteins were loaded with loading buffer (90% NuPAGE LDS
Sample Buffer (4X) (Invitrogen)
10% -Mercaptoethanol) and run at 140V, 1 ½ hrs. The gel was then carefully
transferred to nitrocellulose paper (NCP) in apparatus containing 1liter transfer buffer
(3.02g Tris, 14.4g glycine, 200ml methanol).
When transfer was complete the NCP was placed in blocking solution (5% dry
milk, 50ml TBS-T) for 1hr then washed (5min, 8x) with TBS-T. Primary antibodies
for HER-2/Neu (ratio 1:1500), and -actin (ratio 1:20,000) were added to blocking
solution and Blot was incubated shaking overnight at 4C in solution. Next day the
primary antibodies were washed off blot using TBS-T (5 min, 8x). Secondary
antibody (ratio 1:10,000) was added to blocking solution and added to blot and
incubated at room temperature for 2hrs. Blot was washed with TBS-T (5min, 8x),
bands were visualized using ECL Western Blot Detection Kit (GE Healthcare) and
Typhoon scanner.

2.15 Cell Viability Assay
To analyze the cells health after transfecting the cell viability assay was done
according to the following procedure. Cells were plated using 96-well plate,
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transfected as stated previously, and harvested at different time points (2, 4, and 6
days). At time of harvest Cell Titer-Glo Luminescent Cell Viability Assay substrate
was thawed and equilibriate at room temperature (~1-2hrs). The cell culture plate and
its content was allowed to equilibrate at room temperature 30 min. 100l of substrate
was added to each well and the plate was scanned in the luminometer (Shake 15min,
incubate 20 min, and reading taken at 1 sec intervals.

2.16 Apoptosis Assay
To determine whether the transfection of the mutation snRNAs transfect had
an impact on the life of the cells an apoptosis assay was done according to the
following procedure. The cells were transfected as previously outlined. Apoptosis
assay was done using FITC Annexin V. In brief, transfected cells were washed using
PBS and centrifuged to collect the pelleted cells. 100l of binding buffer was added
and cells were gently re-suspended in buffer. 5l FITC Annexin V + 5l Propidium
Iodide (PI) was added to each sample in dim lighting and incubated in dark at room
temperature for 15 min. An additional 400l of 1X binding buffer was added to each
tube and samples were analyzed via flow cytometry using the Fluorescence-activating
cell sorting (FACS) machine. Cells only sample to calibrate the FACS machine.
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CHAPTER III
RESULTS and DISCUSSION

3.1 Construction of Sequence Mutations
To study the effects the mutated snRNAs U6ATAC and U11 (Appendix 3)
have on the splicing of HER-2/Neu pre-mRNA the first aspect was to generate the
mutant to be transiently transfected into the cells. Using HER-2/Neu gene as a
template the mutants snRNAs were generated to be complementary to the HER-2 premRNA 5’ splice site for introns 1, 2, 6, 8, 12, and 13 (Figure 3). The introns were
primarily chosen because they are located at the 5’ end of the HER-2 gene transcript
and are larger than the remaining HER-2 introns.
Cells were transiently transfected using liposome-based delivery system.
Liposome-based non-viral delivery system is not as effective as viral systems, but it is
a comparable alternative when the overall cell safety is factored (Madeira et al.,
2010).
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Using Fugene 6 reagent transfection system cells were transfected with 3l of
Fugene and 2g of total mutant DNA per well of six well plates along with the
appropriate controls, incubated for 48-72 hrs, then harvested. After experiment and
treatment, different cell assays were done on MDA-MB-453 and T-47D cells to
analyze both the HER-2/Neu mRNA and protein expressions.
It is expected that the mutant U11 snRNAs would forcibly bind to the 5’
splice site of the HER-2 gene, which would compete and inhibit the binding of U1
(the endogenous snRNA for HER-2 introns). U6ATAC

MUTANT SEQUENCE FOR TARGETED INTRONS
snRNA

5’-3’ INTRONIC MUTANT SEQUENCE

U6ATAC I1

GTG TTG TAT GAG ACC CGA GAA GGT T

U6ATAC I2

GTG TTG TAT GGG TCT CGA GAA GGT T

U6ATAC I6

GTG TTG TAT GGC ACA TGA GAA GGT T

U6ATAC I8

GTG TTG TAT GAC TCT TGA GAA GGT T

U6ATAC I12

GTG TTG TAT GTG TCT TGA GAA GGT T

U6ATAC I13

GTG TTG TAT GCC TCA TGA GAA GGT T

U11 I1

CGA AGA TCT CAA AGA CCC CTT CTG TCG T

U11 I2

CGA AGA TCT CAA GGT CTC CTT CTG TCG T

U11 I6

CGA AGA TCT CAA GCA CAT CTT CTG TCG T

U11 I8

CGA AGA TCT CAA ACT CTT CTT CTG TCG T

U11 I12

CGA AGA TCT CAA TGT CTT CTT CTG TCG T

U11 I13

CGA AGA TCT CAA CCT CAT CTT CTG TCG T
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Table 1: Sequence of snRNAs mutations: The sequences for snRNAs U6ATAC
and U11 that mutated to bind complementary to the HER-2/Neu gene in the 5’ splicesite of the corresponding introns (I). The numbers correspond to the targeted intron.

3.2 Inhibitory Effect of snRNA Mutants on MDA-MB-453 and T-47D HER-2
Protein Expression
To quantify and compare protein expression in both MAD-MB-453 and T47D cell line western blot assay was performed using total protein lysate as
previously outlined in 2.14. 48hrs after transfection, cells were harvested, lysed, and
the protein concentration was obtained using the Bradford assay system. To optimize
the western assay, concentrations of proteins: 5g, 10g, 15g were ran on the gel
and observed. It was determined that 5g concentration was sufficient to be able to
quantify protein expression in both cell lines.
Figure 4 and 5 shows the result of the western blot analysis. Figure 4 shows
the data retrieved from HER-2 protein expression in the MDA-MB-453 cell line, and
Figure 5 shows the HER-2 protein expression in T-47D cell line. It is apparent that in
both cell lines there is a variable affect on the protein expression with the transiently
transfected snRNA mutants. In figure 4 cells only were the untreated cells, and
fugene only was simply treated with transfection reagent to compare the data obtained
for the snRNA mutants to. The U6ATAC and U11 snRNA double transfected
mutations for intron 1 show no significant difference in protein expression levels as
compared to the controls. However, in the U6ATAC and U11 snRNA mutations for
introns: 2, 6, 8, 12, and 13, shows significant repression in protein expression.
According to this data we can attribute the repression of protein expression, does
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activate SPLICEi as a direct consequence of transfection of these mutants in MDAMB-453 cell line.

Figure 4: Western Blot showing HER-2/Neu protein expression in MDA-MB-453
mammary carcinoma cells. The upper panel shows HER-2/Neu expression and the
lower panel shows -actin expression as an endogenous control. (A) Actual western
blot, lane 1: Cell only (untreated), lane 2: Fugene only (treated with 3l transfection
reagent only), lanes 3-8: cells treated with mutant snRNAs targeting the various
introns. (B) The quantification of the western blot shown in (A) showing the HER-2
protein expression.
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Figure 5: Western Blot showing HER-2/Neu protein expression in T-47D
mammary carcinoma cells. The upper panel shows HER-2/Neu expression and the
lower panel shows -actin expression as an endogenous control. (A) Actual western
blot, lane 1: Cell only (untreated), lane 2: Fugene only (treated with 3l transfection
reagent only), lanes 3-8: cells treated with mutant snRNAs targeting the various
introns. (B) The quantification of the western blot shown in (A) showing the HER-2
protein expression.
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Figure 5 shows the data for T-47D cell line under the same conditions as
outlined in 2.14. According to the data from figure 5, there is no significant difference
in protein expression due to targeted snRNA mutations for intron 1, similar to that
shown in figure 4 for the MDA-MB-453 cell line. Again similar to the MDA-MB-453
cell line, figure 5 shows that in the T-47D cell line there is significant difference in
the data for the targeted intron 2, 6, 8, and 12. For intron 13 mutations in the T-47D
cell line there was no significant difference in HER-2 protein expression observed.
There appear to be an overall trend within both cell lines, as the targeted
intron number increases the less is the HER-2 protein expression. Perhaps the further
away from the 5’ end of the gene, or the closer to the 3’ end of the gene the greater
the mutant snRNAs U11 and U6ATAC have on down regulating HER-2 protein
expression.
Because of the western blot data for both cell line, it can be said with a degree
of certainty that the transfection of the mutated snRNA chosen to forcibly bind to the
HER-2/Neu gene at the 5’ splice-site, does cause varying degrees of splicing
interference in the pre-mRNA possessing that is reflected in the repression of protein
synthesis for some of the targeted introns of the HER-2 pre-mRNA in mammary
carcinoma cells.
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3.3 HER-2/Neu mRNA Expression Analyzed Via Quantitative Real Time
Polymerase Chain Reaction (qRT-PCR)
To observe the level of HER-2/Neu gene expression during “real-time” qRTPCR was performed as outlined in 2.12. After 48hr incubation of the transfection
RNA was harvested from MDA-MB-453 and T-47D as outlined in 2.8. With the
extracted RNA cDNA was synthesized for both cell lines, MDA-MB-453 and T-47D,
according to 2.10. Using the synthesized cDNA qRT-PCR was performed.
The qRT-PCR analysis was done in triplicates and figure 6 and 8 shows the
HER-2 mRNA expression for both MDA-MB-453 and T-47D cell lines. Figure 7 A,
B, and C, shows the internal validity of the qRT-PCR procedure with HER-2 standard
curve r2=0.986 and GAPDH r2=0.991. GAPDH was the chosen endogenous control
because it is a housekeeping gene that is present in all cell types. Using the
appropriate controls it is with a certain degree of certainty that the data obtained in
the assay is reliable.
The data in figure 6 and 8 shows the level of HER-2/Neu gene expression as
obtains from the qRT-PCR. Figure 6 shows that targeting intron 8 and 12 had
significant effect on gene expression in MDA-MB-453 cell line. The remaining
targeted introns for MDA-MB-453 cell line seem to have no significant effect on
gene expression.
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The data obtained from qRT- PCR for T-47D cell line, as shown in figure 8,
shows that in comparison to the appropriate controls there is no significant difference
in HER-2/Neu gene expression among and of the targeted introns.

Figure 9 A, B, and C shows the qRT-PCR standard curves for T-47D cell line
as well as the amplification plot. HER-2 standard curve r2 = 0.91 and GAPDH r2 =
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0.991.
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The data in figure 9 shows the reliability of the qRT-PCR for T-47D and it can be
said with a degree of certainty that the data obtained is reliable.
It can be said that there is some splicing interference taking place in the
MDA-MB-453 cell line but none that is apparent in the T-47D. Whatever effect is
taking place as a consequence of the mutant snRNA transfected is not reflected in the
overall mRNA expression for both cell lines.

3.4 Mammary Cell Viability After Transfection
Another step in attempting to determine the effect the transfection of the
mutated snRNA may have on mammary carcinoma cells is assessing possible
phenotypically changes that may occur. One way to do this was to determine the
cells’ health after transfection by means of the cell viability assay.
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The cell viability assay was done according to the procedure outlined in 2.15
for both MDA-MB-453 and T-47D cell lines. Figure 10 is a graphical depiction of
data obtained from cell viability assay for MDA-MB-453, and figure 11 data
collected for T-47D cell line.

According to data shown in figure 10 and 11, cell only lanes and fugene 6
lanes in both MDA-MB-453 and T-47D shows steady cell growth on the 2nd, 4th, and
6th days. MDA-MB-453 cells treated with mutant snRNAs (U11 and U6ATAC)
targeting intron 1 and 12 show steady growth in cells on 2nd and 4th day, but on 6th
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day the cells show slight decrease in the number of cells, indicating cells growth
stopped and some cell death may have occurred. T-47D cells with mutant snRNAs
targeting introns 1, 2, 6, 12, and 13 show decrease in cell number, indicating the
mutants may cause cell death possibly due to intrinsic cellular apoptotic mechanisms
or consequence of some extrinsic factors. Further testing, such as longer growing
period before harvesting, would need to be done to determine the validity of this
emerging trend and apoptosis assay to confirm it is due to intrinsic apoptosis.

3.5 Apoptosis in MDA-MB-453 mammary cells
Another assay done with the MDA-MB-453 cell line to determine if the
transfections of mutated snRNAs for introns 1, 2, 6, 8, 12, and 13 of the HER-2/Neu
gene have an effect on the overall viability of the cell lines. To determine if the
increase in cell death observed in cells ttransfected with mutant snRNAs is due to
intrinsic apoptosis pathway an apoptosis assay was done and analyzed via flow
cytometry using Fluorescence-activated Cell Sorting (FACS) machine. To assess the
reason for cell death observed apoptosis assay was performed according to the
procedure outlined in 2.16.
Figure 12 shows data obtained from the Fluorescence-activated Cell Sorting
(FACS) machine. The FACS machine observed 20,000 cells of MDA-MB-453 cell
line per treatment. According to these data, in comparison to fugene 6 treated cells
(negative control) (2.27% apoptosis, ~454 cells) there appear to be more cells
undergoing apoptosis in cells transfected with mutant snRNAs. Based on the result of
the apoptosis assay obtained from FACS analysis, show the increase in cell death
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observed in the transfected cells was most likely due to intrinsic apoptotic pathway.
(Figure 12)
Figure 12 show there is a slight increase in apoptosis with the cells containing
mutations for targeted intron 1 (2.43% = ~486 cells) as compared to the fugene 6
treated cells. Targeting introns 2, 6, 8, 12 and 13 with mutant snRNAs appear to show
more significant increase in apoptosis. Transfected cells targeting intron 2 had
apoptosis at 4% (~800 cells), intron 6 had apoptosis of 4.10% (~820 cells), intron 8
had apoptosis of 3.99% (~800 cells), intron 12 showed apoptosis of 3.43% (~686
cells), and intron 13 showed apoptosis of 5.24% (~1048 cells).

QUANTIFICATION OF APOPTOSIS IN MDA-MB-453 MAMMARY
CARCINOMA CELLS
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Figure 12: Fluorescence-activated cell sorting analysis of apoptosis assay done on
MDA-MB-453 for 20,000 events: Q6 (Quadrant 6) shows the cells undergoing late
stages of apoptosis (A) Apoptosis in fugene 6 only treated cells (negative control) =
2.27% (~454 cells) (B) Apoptosis in cells treated with mutant snRNAs targeting
intron 1= 2.43% (~486 cells). (C) Apoptosis in cells treated with mutant snRNAs
targeting intron 2 = 4.0% (~800 cells). (D) Apoptosis in cells treated with mutant
snRNAs targeting intron 6 = 4.10% (~820 cells). (E) Apoptosis in cells treated with
mutant snRNAs targeting intron 8 = 3.99% (~800 cells). (F) Apoptosis in cells treated
with mutant snRNAs targeting intron 12 = 3.43% (~686 cells). (G) Apoptosis in cells
treated with mutant snRNAs targeting intron 13 = 5.24% (~1048 cells).

According to the apoptosis data obtained or MDA-MB-453 cell line it appear
that the transfected snRNA mutations does have some effect of the number of cells
undergoing apoptosis (Figure 12). The effect is consistently more that the negative
control. Across all samples snRNAs, the negative control fugene 6 only treated cells
have the least number of cells undergoing apoptosis (~454 cells) and greatest number
of cells undergoing apoptosis was seen when intron 13 was targeted (~1048 cells)
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(Figure 12).

This apoptosis data is consistent with the trend observed with the

HER-2 protein expression, where there was a decrease in the protein expression. The
apoptosis assay data was also consistent with the data obtained from the cell viability
assay, which showed a decrease in the number of viable cells in the transfected
population as compared to the cells not transfected with the mutant snRNAs.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Conclusions
The novel experiment of mutating U12-dependent (minor class) snRNA U11
and U6ATAC to be over-expressed in the U2-depedent (major class) introns as a
method of activating splicing interference as an attempt to down regulate HER-2/Neu
mammary carcinoma gene show very promising results.
After analyzing the HER-2 protein expression a down regulation trend was
evident as the introns number targeted increased, got further away from the 5’ end of
the HER-2 pre-mRNA, and closer to the 3’ end, the less HER-2 protein was
expressed. Intron 1 is the largest of the targeted introns but repression of the HER-2
protein was the least when targeting intron 1 in both MDA-MB-453 and T-47D cells.
Therefore, based on the HER-2 protein expression data, size does not appear to be a
determining factor in the level of protein down regulation.
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Perhaps there is some intrinsic mechanism that corrected the splicing
interference that may be housed in the larger intron, and the size of the intron may
also play a role by allowing surface area to facilitate any possible corrections the cells
may have in place.
The qRT-PCR data for both MDA-MB-453 and T-47D showed little down
regulation in HER-2/Neu mRNA expression. Only in MDA-MB-453 cell line with
mutant snRNA targeting introns 6 and 12 showed some down regulation in mRNA
expression, but little to no down regulation in the remaining targeted introns.
Whatever effect the mutant snRNA may have on the mRNA level it appears to be
very minimal.
For the cells viability assay cell were transfected and harvest after 2, 4, and 6
days in order to assess the growth of viable cells after being transfected with the
mutant snRNAs. The cell viability data show some activation of SPLICEi that lead to
less number of viable cells particularly affect the 6th day of incubation with the
mutants. The decrease in the number of viable cells was clearly observed in T-47D
mammary carcinoma cell line. Further testing needs to be done in order to better
observe the cells’ viability perhaps with longer incubation periods an amplification of
the effect the mutant snRNAs are having on cells viability can be clearly observed.
To further observe the effect the mutant snRNAs are having on the observed
decrease in the number of viable cells an apoptosis assay was done on mutant MDAMB-453 cells. MDA-MB-453 mammary carcinoma cells were incubated for 72 hrs,
dyed and analyzed by the fluorescence activated cell sorting (FACS) machine. The
data showed an increase in the number of cells undergoing apoptosis was greater in
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the mutant snRNAs transfected cells than the negative control (fugene 6 only) cells. It
is possible that longer incubation period would enhance, and clearly show whether
there is a definite effect on apoptosis on these mammary carcinoma cells. To further
observe the effect the mutant snRNAs are having on the mammary carcinoma cells
the apoptosis assay would also be done on the T-47D mammary carcinoma cells.
More work need to be done in order to make a definitive conclusion about the
magnitude of the SPLICEi activity. Apart from longer incubation periods before
harvesting for HER-2 protein and RNA with the already targeted introns, perhaps
attempting combinatory transfection targeting multiple introns at once would give an
amplified effect in order to have a more definitive conclusion.
As a direct result of the emerging trend observed in the HER-2 protein
expression, new introns should be targeted at the 3’ end of the HER-2 pre-mRNA,
individually and in combination with other introns. The newly targeted introns may
show more down regulation in protein expression and may have a greater effect that
could also be better observed at the mRNA expression level.
Only 2g of mutant DNA was used in the transfections, an increase in the
concentration of mutant U11 and U6ATAC transfected may also show an
amplification in the down regulation of the HER-2 protein and mRNA expression.
Exploring methods of transfection can increase transfection efficiency and possibly
amplify the initial results of down regulation HER-2 expression observed.
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APPENDIX
Appendix 1: Sequence of Primers: End PCR

1. U6ATAC WT - 5’ – GTG TTG TAT GAA AGG AGA GA – 3’
2. U6ATAC I1 - 5’ – GTG TTG TAT GAG ACC C – 3’
3. U6ATAC I2 - 5’ – GTG TTG TAT GGG TCT C – 3’
4. U6ATAC I6 - 5’ – GTG TTG TAT GGC ACA T – 3’
5. U6ATAC I8 - 5’ – GTG TTG TAT GAC TCT T – 3’
6. U6ATAC I12 - 5’ – GTG TTG TAT GTG TCT T – 3’
7. U6ATAC I13 - 5’ – GTG TTG TAT GCC TCA T – 3’
8. U11 WT - 5’ – AAA AAG GGC TTC TGT CGT G – 3’
9. U11 I1 - 5’ – AAA GAC CCC TTC TGT CGT G – 3’
10. U11 I2 - 5’ – AAG GTC TCC TTC TGT CGT G – 3’
11. U11 I6 - 5’ – AAG CAC ATC TTC TGT CGT G – 3’
12. U11 I8 - 5’ – AAA CTC TTC TTC TGT CGT G – 3’
13. U11 I12 - 5’ – AAT GTC TTC TTC TGT CGT G – 3’
14. U11 I13 - 5’ – AAC CTC ATC TTC TGT CGT G – 3’
15. U6ATAC REV - 5’ – AGT AGG TGG CAA TGC CT – 3’
16. U11 REV - 5’ – CAC CAG CTG CCC AAA TAC – 3’
17. U6ATAC RT - 5’ – ACG ATG GTT AGA TGC CAC G – 3’
18. U11 RT - 5’ – AGG GCG CCG GGA CCA ACG– 3’
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Appendix 2: Sequence of qRT PCR Primers: All primers are in 5’ to 3’ direction

1. U6ATAC Intron 1- GTG TTG TAT GAG ACC CGA GAA GGT T
2. U6ATAC Intron 2- GTG TTG TAT GGG TCT CGA GAA GGT T
3. U6ATAC Intron 6 - GTG TTG TAT GGC ACA TGA GAA GGT T
4. U6ATAC Intron 8 - GTG TTG TAT GAC TCT TGA GAA GGT T
5. U6ATAC Intron 12 - GTG TTG TAT GTG TCT TGA GAA GGT T
6. U6ATAC Intron 13 - GTG TTG TAT GCC TCA TGA GAA GGT T
7. U11 Intron 1 - CGA AGA TCT CAA AGA CCC CTT CTG TCG T
8. U11 Intron 2 - CGA AGA TCT CAA GGT CTC CTT CTG TCG T
9. U11 Intron 6 - CGA AGA TCT CAA GCA CAT CTT CTG TCG T
10. U11Intron 8 - CGA AGA TCT CAA ACT CTT CTT CTG TCG T
11. U11 Intron 12 - CGA AGA TCT CAA TGT CTT CTT CTG TCG T
12. U11 Intron 13 - CGA AGA TCT CAA CCT CAT CTT CTG TCG T

51

Appendix 3: Mutations of Specific snRNA

INTRON

WT 5’ SS
HER-2

U11 WT
5’-3’

U11 MUT
5’-3’

U6atac WT
5’-3’

1

GGGTCT

AAAGGG

AGACCC

AAAGGA

U6atac
MUT
5’-3’
AGACCC

2

GAGACC

AAAGGG

GGTCTC

AAAGGA

GGTCTC

6

ATGTGC

AAAGGG

GCACAT

AAAGGA

GCACAT

8

AAGAGT

AAAGGG

ACTCTT

AAAGGA

ACTCTT

12

AAGACA

AAAGGG

TGTCTT

AAAGGA

TGTCTT

13

ATGAGG

AAAGGG

CCTCAT

AAAGGA

CCTCAT
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Binding

U11 3’

C-C-C-A-G-A
| | | | | |
HER2 5’ G-G-G-T-C-T
| | | | | |
U6atac 3’C-C-C-A-G-A
U11 3’
C-T-C-T-G-G
| | | | | |
HER2 5’ G-A-G-A-C-C
| | | | | |
U6atac 3’ C-T-C- T- G-G
U11 3’
T-A-C-A-C-G
| | | | | |
HER2 5’ A-T-G-T-G-C
| | | | | |
U6atac 3’ T-A-C-A-C-G
U11 3’
T-T-C-T- C- A
| | | | | |
HER2 5’ A-A-G-A-G-T
| | | | | |
U6atac 3’ T-T- C-T- C-A
U11 3’
T-T-C-T- G-T
| | | | | |
HER2 5’ A-A-G-A-C-A
| | | | | |
U6atac 3’ T- T- C-T-G-T
U11 3’
T-A-C-T-C-C
| | | | | |
HER2 5’ A-T-G-A-G-G
| | | | | |
U6atac 3’ T-A-C-T- C-C
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